Cybin announces closing of the oversubscribed private placement of u.s. $150 million

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, is pleased to announce the closing of the company's previously announced private placement (the “private placement”) of 348,837,210 common shares in the capital of the company (the “common shares”) at a price of u.s.$0.43.
CYBN Ratings Summary
CYBN Quant Ranking